期刊
CANCER LETTERS
卷 412, 期 -, 页码 283-288出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2017.10.008
关键词
Liver cancer; Hepatocellular carcinoma; Early diagnosis; Personalized therapy
类别
资金
- State Key Project [2015ZX09J15107]
- National Natural Science Foundation of China [81522035, 81521091, 81372206, 81472768]
- Shanghai Committee of Science and technology [15431901600, 16QA1404900]
Liver cancer ranks the sixth in cancer incidence and the second in tumor related mortality worldwide, with over half of the new cases and deaths occur in China. Because of difficulties in early diagnosis, rapid progression and lack of targeted drugs, the survival rate of liver cancer is extremely low. The existence of extraordinary heterogeneity has greatly limited the progress in early detection, molecular classification and targeted therapy of live cancer, owing to its varied risk factors, genetic susceptibilities, morphological diversity and microenvironmental discrepancies. Based on the heterogeneity of individual patients, precision medicine brings a new dimension to cancer personalized diagnosis and more-targeted treatment, and even give us access to pre-clinical screening of tumors in high risk populations. The present review article will provide progresses in precision diagnosis, molecular classification, signaling disregulation, preclinical models and personalized treatment of liver cancer in China. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据